Mode
Text Size
Log in / Sign up
N/A N=54 Randomized Treatment

Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers

Smoking Cessation · Overweight · Obesity

Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcome: Primary: Number of Participants With Verified Smoking Cessation (Abstinence) — 7; 5 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nicotine patch (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Nov 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Verified Smoking Cessation (Abstinence)
7; 5
SECONDARY
Percent Weight Change
1.47; 1.79

Summary

This project will be a randomized clinical trial testing the efficacy of an internet-administered smoking cessation treatment for overweight and obese smokers. Research on internet-administered behavioral treatments for smoking cessation has found that compared to control treatments (e.g., self-help materials), cessation rates in internet-administered treatments are significantly higher. Research testing the applicability of these treatments to overweight and obese individuals has not yet been conducted. Given that a substantial portion of smokers are also overweight and at elevated cardiovascular risk, there is a need for directed treatment efforts for this group. The current trial proposes to be the first to test the effectiveness of internet-administered smoking cessation treatment for overweight and obese (BMI≥25) smokers. Adult participants will be randomized to receive 12 weeks of internet-administered treatment consisting of either: a) standard smoking cessation treatment with general health education, or b) standard smoking cessation treatment with cognitive behavioral therapy (CBT) for weight concerns. Participants in both conditions will receive open-label treatment with the 21 mg transdermal nicotine patch.

Eligibility Criteria

Inclusion Criteria

  • Smoking 10 or more cigarettes per day
  • Regular access to the internet
  • BMI>=25

Exclusion Criteria

  • Type I diabetes or Type II diabetes requiring medication
  • Alcohol or drug dependence within the past year
  • Females with current pregnancy or breastfeeding or intention to become pregnant within the next 12 months
  • Uncontrolled hypertension
  • Severe chronic obstructive pulmonary disease
  • Use of an investigational drug within 30 days or current participation in another clinical trial
  • Current use of tobacco products other than cigarettes or use of marijuana
  • Use of nicotine replacement therapy, clonidine, varenicline, bupropion, or nortriptyline within the month prior to enrollment
  • Use of a medication that might affect weight or appetite
  • History of allergic reactions to adhesives.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01259466). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search